Nvidia Faces New Hurdles in China as Energy Rules Threaten AI Chip Sales 
KKR Nears Deal to Acquire Japan’s Topcon, Shares Hit Record High 
PsiQuantum Eyes $750M Funding to Scale Quantum Chip Production with BlackRock's Backing 
SoftBank Acquires AI-Focused Chipmaker Ampere in $6.5B Deal 
Sustainable Aviation Fuel Faces Major Setbacks in Race to Meet 2030 Targets 
NVIDIA CEO Jensen Huang Reconsiders Quantum Computing at GTC 2025 
Italy Targets Meta, X, LinkedIn with $1.1B VAT Claim in Landmark Tax Case 
Trump’s Proposed Port Fees Spark Backlash from U.S. Exporters and Energy Industry 
Anduril Eyes Global Expansion Amid Trump-Era Defense Shift and AI Partnership 
Instagram Experiences Widespread Outage, Thousands Affected in the U.S. 
Elon Musk Merges xAI with X in $113B Deal to Build AI-Powered Tech Giant 
Alibaba Stock Gets Boost as Mizuho Touts AI Potential and Hikes Price Target 
Samsung Faces Investor Scrutiny Over AI Struggles, Promises Growth Amid Challenges 
China Backs Viral AI Startup Manus Amid Global Buzz and Domestic Rollout 
BYD to Launch 500 Ultra-Fast EV Charging Stations in April, Doubling Tesla’s Speed 
Robinhood Unveils High-Yield Banking, AI Investing Tools to Disrupt Traditional Finance 
Nippon Steel Eyes $7B Investment to Salvage U.S. Steel Deal Amid White House Talks 
Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the site's inauguration, confirmed plans for further investments in the coming years.
The Hyderabad facility, announced last year, aims to accelerate medicine development through cutting-edge technology. By year-end, it is expected to employ 2,000 people, with 300 already on board, according to Som Chattopadhyay, Amgen's national executive for India.
Amgen’s expansion aligns with India’s growing role as the “pharmacy of the world,” attracting global pharmaceutical giants. The company’s presence in Hyderabad coincides with the BioAsia conference, where key executives from Amgen, Eli Lilly (NYSE: LLY), Novartis (SIX: NOVN), and leading Indian pharma firms will participate.
The U.S. and India recently initiated talks for a trade deal to strengthen collaboration in emerging technologies. U.S. Consul General in Hyderabad, Jennifer Larson, highlighted Amgen’s expansion as a prime example of this partnership. However, potential U.S. tariffs on pharmaceutical imports—reportedly 25% or higher—could impact Indian drugmakers, as the U.S. remains their largest market.
With Amgen’s strategic investment, India’s biotech sector continues to gain global attention, reinforcing its position as a key hub for pharmaceutical innovation.
